[Comparison Study of Visual Function and Patient Satisfaction in Patients with Monovision and Patients with Bilateral Multifocal Intraocular Lenses]

Objective: To compare visual function and patient satisfaction in patients with bilateral diffractive multifocal intraocular lenses (IOL) and patients with monofocal IOL monovision.

Methods: Prospective nonrandomized controlled study. This study comprised consecutive bilateral cataract patients 45 cases (90eyes) between January 2011 and March 2012. All cases were divided into two groups: multifocal IOL group (23 patients) having implantation of AcrySof ReSTOR +3D(SN6AD1) multifocal IOL, monovision group (22 patients) having implantation of AcrySof IQ (SN60WF) IOL. Parameters analyzed 3 months postoperatively included binocular uncorrected distance, intermediate, and near visual acuities; stereo vision;photopic and mesopic contrast sensitivity function without glare. Parameters analyzed 6 months postoperatively included spectacle independence; subjective visual symptoms; and patient satisfaction. The independent-samples t test were used to compare the measure data which met normal distribution. The chi-square test was applied to compare categorical variables.

Results: There were no significant differences between groups in bilateral uncorrected distance vision (0.13 ± 0.06, 0.17 ± 0.19; Z = 1.755, P = 0.086) , intermediate (0.34 ± 0.05,0.33 ± 0.06; Z = -0.821, P = 0.416) , and near vision (0.35 ± 0.06, 0.41 ± 0.09; Z = 2.117, P = 0.051) . There were significant differences between groups in stereo vision (Median: 150″, 525″; Z = -2.092, P = 0.036) . Percentage of patients wearing spectacle were less than 10% in all groups [91.3% (21/23), 90.9% (20/22) ].On the questionnaire, patients in multifocal IOL group complained with double vision, trouble in night vision and halo(21.7%).

Conclusions: Pseudophakic monovision and MIOL achieved distance vision, intermediate vision and near vision. But monovision was no risk for disturbing visual symptoms associated with multifocal IOL.